BioSpace News Archive

Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2022 financial results before the market opens on Thursday, November 3, 2022 via press release, which will be available on the Company’s website at www.geron.com/investors.

Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it will release financial results for the first nine months of 2022, after U.S. markets close on Tuesday, November 15, 2022.

According to Vision Research Reports, the global proteinase K market size was garnered at USD 3.7 billion in 2021 and is expected to hit around USD 7.98 billion by 2030, growing at a CAGR of 8.92% from 2022 to 2030.

Latest Study on “Cancer Immunotherapy Drug Discovery Outsourcing Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Hyperfine, Inc., the creator of Swoop®, the world’s first FDA-cleared portable MRI system™, announced that it will report financial results for the third quarter 2022 on Thursday, November 10, 2022.

NANOBIOTIX announced that it will report its financial results for the third quarter ended September 30, 2022, on Wednesday, November 9, 2022, after the close of the US market.

Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, today announced that it has initiated the LYNX Phase 2 clinical trial at Rare Disease Research, LLC in Atlanta, Georgia.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022.

Latest Study on “Liver Cancer Diagnostics Market Size, Share, Trends, Growth, Production, Consumption, Revenue, Company Analysis and Forecast 2022-2030”.

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company is scheduled to release its third quarter 2022 financial results after the market closes on Thursday, November 3, 2022.